Skip to main content

Advertisement

Table 3 Univariate and multivariate Cox regression analysis for overall survival (OS)

From: Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

Characteristics Univariate analysis Multivariate analysis
Median OS (months) HR 95% CI p HR 95% CI p
All patients 30.3       
Age
 < 55 22.4 1.72 0.88–3.37 0.113    
 ≥ 55 23.4       
Gender
 Male 23.3 0.70 0.36–1.38 0.307    
 Female 20       
Primary tumor location
 Colon 22.4 0.78 0.39–1.58 0.497    
 Rectum 22.85       
Primary tumor surgery
 Yes 39.4 0.17 0.08–0.37 < 0.0001 0.37 0.12–1.11 0.075
 No 11.6       
Response (12 weeks) (RECIST)
 Favorable 41.6 0.26 0.06–1.14 0.074 0.1 0.02–0.58 0.011*
 Adverse 16.8       
Response (24 weeks) (RECIST)
 Favorable 48.6 0.51 0.22–1.20 0.123    
 Adverse 14.8       
K-RAS status
 Mutated 36.9 1.95 0.96–3.97 0.064 1.58 0.68–3.68 0.289
 Wild-type 55.4       
Metastasis surgery
 Operated 68.4 0.35 0.15–0.81 0.014 0.39 0.12–1.24 0.111
 Non-operated 31.1       
Synchronous metastasis
 Yes 32.1 15.89 2.04–123.35 0.008 18.33 1.52–221.18 0.022*
 No 68.4       
CEA Basal
 High 39.4 1.96 0.84–4.57 0.121    
 Standard 55.4       
Basal Ca 19.9
 High 22.4 1.68 0.87–3.24 0.123    
 Standard 55.4       
CTC1
 Favorable 21.6 0.32 0.72–2.79 0.319    
 Adverse 23.5       
CTC1 VEGFR
 Yes 66.5 0.53 0.25–1.15 0.109    
 No 36.9       
CTC2
 Favorable 39 1.36 0.62–3.01 0.442    
 Adverse 55.4       
CTC2 VEGFR
 Yes 36.9 1.44 0.31–6.66 0.640    
 No 41.6       
CTC3
 Favorable 55.4 0.52 0.22–1.26 0.149 0.35 0.12–0.99 0.049*
 Adverse 22.4       
CTC3 VEGFR
 Yes 22.4 1.04 0.23–4.81 0.958    
 No 30.9       
  1. *: Statistically significant
  2. CTC: circulating tumor cell; OS: overall survival; HR: hazard risk; CI: confidence interval; VEGFR: vascular endothelial growth factor receptor positive; RECIST: Response Evaluation Criteria in Solid Tumors; p: p value